
Hormone Therapy May Boost GLP-1 Weight-Loss Drugs in Postmenopausal Women
A retrospective study of 120 postmenopausal women found that adding menopausal hormone therapy to tirzepatide led to about 19.2% total body weight loss over roughly 18 months, versus 14% with tirzepatide alone, a statistically significant difference. The study is not randomized and did not distinguish hormone therapy types; researchers say controlled trials are needed to confirm the potential synergy and to explore cardiometabolic effects, building on prior work suggesting similar benefits with other GLP-1 drugs plus hormone therapy.


